Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Cardiovascular Risk of Nonsteroidal Anti-Inflammatory Drugs: An Under-Recognized Public Health Issue.

Varga Z, Sabzwari SRA, Vargova V.

Cureus. 2017 Apr 8;9(4):e1144. doi: 10.7759/cureus.1144. Review.

2.

Clinical Pharmacology and Cardiovascular Safety of Naproxen.

Angiolillo DJ, Weisman SM.

Am J Cardiovasc Drugs. 2017 Apr;17(2):97-107. doi: 10.1007/s40256-016-0200-5. Review.

3.

Nonsteroidal Anti-Inflammatory Drugs and the Kidney.

Hörl WH.

Pharmaceuticals (Basel). 2010 Jul 21;3(7):2291-2321. Review.

4.

Non-Steroidal Anti-Inflammatory Drugs: An Overview of Cardiovascular Risks.

Meek IL, Van de Laar MA, E Vonkeman H.

Pharmaceuticals (Basel). 2010 Jul 7;3(7):2146-2162. Review.

5.

Assessing the negative impact of phenyl alkanoic acid derivative, a frequently prescribed drug for the suppression of pain and inflammation, on the differentiation and proliferation of chondrocytes.

Gumustas SA, Yilmaz İ, Isyar M, Sirin DY, Batmaz AG, Ugras AA, Oznam K, Ciftci Z, Mahirogullari M.

J Orthop Surg Res. 2016 Jun 30;11(1):70. doi: 10.1186/s13018-016-0406-x.

6.

Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective.

Patrono C.

Br J Clin Pharmacol. 2016 Oct;82(4):957-64. doi: 10.1111/bcp.13048. Epub 2016 Jul 18. Review.

PMID:
27317138
7.

Inhibition of the Prostaglandin Transporter PGT Lowers Blood Pressure in Hypertensive Rats and Mice.

Chi Y, Jasmin JF, Seki Y, Lisanti MP, Charron MJ, Lefer DJ, Schuster VL.

PLoS One. 2015 Jun 29;10(6):e0131735. doi: 10.1371/journal.pone.0131735. eCollection 2015.

8.

Non-interventional management of resistant hypertension.

Doumas M, Tsioufis C, Faselis C, Lazaridis A, Grassos H, Papademetriou V.

World J Cardiol. 2014 Oct 26;6(10):1080-90. doi: 10.4330/wjc.v6.i10.1080. Review.

9.

CG100649, a novel COX-2 inhibitor, inhibits colorectal adenoma and carcinoma growth in mouse models.

Kim SH, Margalit O, Katoh H, Wang D, Wu H, Xia D, Holla VR, Yang P, DuBois RN.

Invest New Drugs. 2014 Dec;32(6):1105-12. doi: 10.1007/s10637-014-0144-z. Epub 2014 Aug 3.

10.

Influence of celecoxib on the vasodilating properties of human mesenteric arteries constricted with endothelin-1.

Grześk G, Szadujkis-Szadurska K, Matusiak G, Malinowski B, Gajdus M, Wiciński M, Szadujkis-Szadurski L.

Biomed Rep. 2014 May;2(3):412-418. Epub 2014 Jan 29.

11.

Cardiovascular comorbidity in rheumatic diseases: a focus on heart failure.

Wright K, Crowson CS, Gabriel SE.

Heart Fail Clin. 2014 Apr;10(2):339-52. doi: 10.1016/j.hfc.2013.10.003. Epub 2014 Jan 10. Review.

12.

Cyclooxygenase-2 in endothelial and vascular smooth muscle cells restrains atherogenesis in hyperlipidemic mice.

Tang SY, Monslow J, Todd L, Lawson J, Puré E, FitzGerald GA.

Circulation. 2014 Apr 29;129(17):1761-9. doi: 10.1161/CIRCULATIONAHA.113.007913. Epub 2014 Feb 11.

13.
14.

Rheumatoid arthritis and cardiovascular disease: an update on treatment issues.

Barbhaiya M, Solomon DH.

Curr Opin Rheumatol. 2013 May;25(3):317-24. doi: 10.1097/BOR.0b013e32835fd7f8. Review.

15.

The effects of bariatric surgery weight loss on knee pain in patients with osteoarthritis of the knee.

Edwards C, Rogers A, Lynch S, Pylawka T, Silvis M, Chinchilli V, Mosher T, Black K.

Arthritis. 2012;2012:504189. doi: 10.1155/2012/504189. Epub 2012 Dec 3.

16.

A systematic review of the effect of paracetamol on blood pressure in hypertensive and non-hypertensive subjects.

Turtle EJ, Dear JW, Webb DJ.

Br J Clin Pharmacol. 2013 Jun;75(6):1396-405. doi: 10.1111/bcp.12032. Review.

17.

Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis.

Liao KP, Solomon DH.

Rheumatology (Oxford). 2013 Jan;52(1):45-52. doi: 10.1093/rheumatology/kes243. Epub 2012 Sep 16. Review.

18.

Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649.

Skarke C, Alamuddin N, Lawson JA, Cen L, Propert KJ, Fitzgerald GA.

Clin Pharmacol Ther. 2012 Jun;91(6):986-93. doi: 10.1038/clpt.2012.3. Epub 2012 Jan 25.

19.

Reducing Adverse Self-Medication Behaviors in Older Adults with Hypertension: Results of an e-health Clinical Efficacy Trial.

Neafsey PJ, M'lan CE, Ge M, Walsh SJ, Lin CA, Anderson E.

Ageing Int. 2011 Jun;36(2):159-191. Epub 2010 Dec 8.

20.

Characteristics and molecular basis of celecoxib modulation on K(v)7 potassium channels.

Du XN, Zhang X, Qi JL, An HL, Li JW, Wan YM, Fu Y, Gao HX, Gao ZB, Zhan Y, Zhang HL.

Br J Pharmacol. 2011 Nov;164(6):1722-37. doi: 10.1111/j.1476-5381.2011.01483.x.

Supplemental Content

Support Center